Characterization of a commercial EPID-based in-vivo dosimetry and its feasibility and implementation for treatment verification in Malaysia

Abstract Introduction: In vivo dosimetry verification is currently a necessity in radiotherapy centres Europe countries as one of the tools for patient-specific QA, and now its demand rising developed countries, such Malaysia. The aim this study to characterize commercial EPID-based implementation treatment Materials Methods: work, sensitivity performance commercially available system, EPIgray® (DOSIsoft, Cachan, France), were qualitatively evaluated prior use at our centre. EPIgray response dose linearity, field size, off-axis, position, angle dependency tests performed against TPS calculated 6 MV 10 photon beams. Relative deviations total isocentre different depths water. measured was validated by using IMRT VMAT prostate plan. All calculation points beam suggested TG-119 with accepted tolerance ±10% threshold. Results: reported good agreement position dose, being within 5% both energy ranges. average deviation less than ±2% ±7% beams, respectively, test. A clinical evaluation plan gave ±3% energies. While plan, 95% 100% all created lie below ±5% energy, respectively. Conclusion: summary, based on results preliminary characterization, believed an important tool beneficial be implemented IMRT/VMAT plans Malaysia, especially verification, alongside existing pre-treatment verification.